Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticala and Consumer Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Company is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment has been moved to Cinven which operates as an independent company called Envu.

  • Revenue in USD (TTM)54.79bn
  • Net income in USD5.16bn
  • Incorporated1952
  • Employees102.30k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAYX.N:GER since
announced
Transaction
value
Blackford Analysis LtdDeal completed18 Jan 202318 Jan 2023Deal completed-0.37%--
Targenomix GmbHDeal completed10 Nov 202210 Nov 2022Deal completed13.01%--
Gloryfeel GmbHDeal completed08 Mar 202208 Mar 2022Deal completed12.08%--
Data delayed at least 15 minutes, as of Feb 02 2023 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DuPont de Nemours Inc14.18bn1.16bn36.83bn28.00k32.391.4814.782.602.293.6327.8450.150.31483.545.49506,571.402.71-0.22273.11-0.289235.0531.608.62-1.611.995.110.3173--16.15-19.13172.14-15.09-25.20-26.30
Iqvia Holdings Inc14.31bn1.18bn43.37bn85.00k38.008.1119.473.036.156.1574.4328.780.593--5.76181,101.304.941.776.252.1434.7234.308.343.64--5.160.69860.0022.1415.28246.2468.0831.30--
Bayer AG (ADR)54.79bn5.16bn60.29bn102.30k11.921.366.031.101.311.3113.9411.540.40281.604.74549,875.203.82-1.375.10-1.7762.3259.999.48-3.730.77244.890.5193--6.484.76106.42-23.200.2547-5.52
Moderna Inc21.39bn11.77bn66.96bn2.70k6.303.755.533.1327.6527.6550.6946.490.91062.937.337,922,222.0050.0941.1777.8866.7879.20--55.0052.351.80--0.05990.002,199.12179.441,733.33--53.67--
Zoetis Inc8.01bn2.07bn78.21bn12.10k38.3516.7930.959.774.384.3816.9410.000.58491.146.84661,735.6015.0813.7917.9316.0470.1968.7525.7823.941.4812.190.584722.5316.499.7324.3619.9317.1720.72
Vertex Pharmaceuticals Incorporated8.70bn3.27bn81.44bn3.90k25.046.2523.839.3612.6712.6733.6950.770.59342.897.002,230,913.0022.3218.0126.4021.8788.0087.7737.6229.174.5532.160.03280.0022.0634.79-13.63--32.96--
Regeneron Pharmaceuticals Inc13.71bn5.37bn82.55bn10.37k15.993.8514.486.0247.4047.40120.98197.050.5340.89672.491,322,357.0020.9225.6424.0029.9985.3988.5139.1739.114.5220.540.1119--89.1427.02129.8655.241.52--
Data as of Feb 02 2023. Currency figures normalised to Bayer AG's reporting currency: US Dollar USD

Institutional shareholders

0.11%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 20222.04m0.05%
Pacer Advisors, Inc.as of 05 Jan 2023801.80k0.02%
Altrius Capital Management, Inc.as of 30 Sep 2022418.28k0.01%
McGinn Investment Management, Inc.as of 30 Sep 2022341.00k0.01%
BlackRock Advisors LLCas of 20 Apr 2022265.64k0.01%
Arrowstreet Capital LPas of 30 Nov 2022144.86k0.00%
Envestnet Asset Management, Inc.as of 30 Nov 2022141.26k0.00%
Cambiar Investors LLCas of 30 Nov 2022135.00k0.00%
Olive Street Investment Advisers LLCas of 25 Jan 202382.17k0.00%
Yousif Capital Management LLCas of 31 Dec 202265.70k0.00%
More ▼
Data from 30 Sep 2022 - 25 Jan 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.